Join
Live feed
·
PRReleasevia Quantisnow
Axsome Therapeutics Inc. logo

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

ByQuantisnow·Wall Street's wire, on your screen.
AXSM· Axsome Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AXSM (Axsome Therapeutics Inc.) and more on Quantisnow.